

L5 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:1459108 CAPLUS Full-text  
 DN 149:576645

TI Preparation of tricyclic compounds such as pyrrolobenzoxazepine derivatives and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis

IN Sugita, Kazuyuki; Otsuka, Masaki; Oki, Hitoshi; Haginoya, Noriyasu; Ichikawa, Masanori; Ito, Masao

PA Daiichi Sankyo Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 1516pp.


CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2008291018	A	20081204	JP 2008-114684	20080424
PRAI	JP 2007-115119	A	20070425		
OS	MARPAT 149:576645				
GI					



AB The title compds. [I; R1 = aryl or heteroaryl which may have 1 to 3 substituents; R2, R2a = H, halo, cyano, etc.; R3 = H, halo, alkyl, etc.; R4 = carboxyl, carboxycarbonyl, carboxyalkenyl, etc.; X = CH2, O, S; Y = N, CR3a; R3a = same as defined for R3; Z = N, CR3aa; R3aa = same as defined for R3; ring (N) = benzene or pyridine ring] are prepared I inhibit squalene synthetase and cholesterol synthesis. Thus, 2-(2-(2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-10-fluoro-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl)-2H-1,2,3,4-tetrazol-5-yl)acetic acid was prepared in a multistep process starting from 2-bromo-4-chloro-6-fluoroaniline and 2,5-dimethoxytetrahydrofuran. Compds. of this invention showed IC50 values of 0.56 nM to 7.6 nM against rat squalene synthetase.

IT 937062-99-2P 937064-06-9P 937064-14-7F  
 937064-19-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tricyclic compds. such as pyrrolobenzoxazepine derivs. and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis)

RN 937062-99-2 CAPLUS

CN 5-Oxazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]-, methyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937064-08-9 CAPLUS

CN 5-Oxazolebutanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]-, methyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937064-14-7 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]-, methyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937064-19-2 CAPLUS


CN 5-Oxazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]-4-methyl-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:352510 CAPLUS Full-text  
 DN 148:347355  
 TI Preventive or therapeutic agent for respiratory disease  
 IN Matsumoto, Tatsumi  
 PA Takeda Pharmaceutical Company Limited, Japan  
 SO PCT Int. Appl., 93pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008032696	A1	20080320	WO 2007-JP67634	20070911
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LG, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	JP 2006-247082	A	20060912		
OS	MARPAT 148:347355				
GI					




AB An agent for suppressing both progression and acute exacerbation of decreased respiratory function with age in respiratory disease, comprising a compound having a squalene synthase inhibitory action and represented by the formula: (I) (wherein R1 represents a hydrogen atom or a hydrocarbon group which may be substituted; R2 and R3 are the same or different and represent a hydrogen atom, a hydrocarbon group which may be substituted or the like; X' represents a carboxyl group which may be esterified, a carbamoyl group which may be substituted, a hydroxy group which may be substituted, an amino group which may be substituted, or a group constituted by a heterocyclic residue which has a deprotonatable hydrogen atom and may be substituted; the ring A represents a benzene ring or a heterocyclic ring which may be substituted; the ring J' represents a 7- or 8-membered heterocyclic ring containing 3 or less heteroatoms as ring constituent atoms, and the ring J' may further have a substituent other than R1, R2, R3 and X').

IT 839724-36-6  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (benzoxacepinylpiperidine analogs and prodrugs as squalene synthase inhibitors and preventive or therapeutic agents for respiratory disease)

RN 839724-36-6 CAPLUS  
 CN 1,2,4-Oxadiazole-5-pentanoic acid,  
 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-

1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2007:538026 CAPLUS Full-text  
 DN 147:9956

TI Preparation of tricyclic compounds such as pyrrolobenzoxazepine derivatives and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis

IN Sugita, Kazuyuki; Otsuka, Masami; Oki, Hitoshi; Haginoya, Noriyasu; Ichikawa, Masanori; Itoh, Masao

PA Daiichi Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 1709pp.


CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007055093	A1	20070518	WO 2006-JP321056	20061023
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1939205	A1	20080702	EP 2006-832385	20061023
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
PRAI	JP 2005-306663	A	20051021		
	WO 2006-JP321056	W	20061023		
OS	MARPAT 147:9956				
GI					



I

AB The title compds. I [R1 = aryl or heteroaryl which may have 1 to 3 substituents; R2, R2a = H, halo, cyano, etc.; R3 = H, halo, alkyl, etc.; R4 = carboxyl, carboxycarbonyl, carboxyalkenyl, etc.; X = CH2, O, S; Y = N, CR3a; R3a = same as defined for R3; Z = N, CR3aa; R3aa = same as defined for R3; ring (N) = benzene or pyridine ring] are prepared I inhibit squalene synthetase and cholesterol synthesis. Thus, 2-(2-(2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-10-fluoro-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl)-2H-1,2,3,4-tetrazol-5-yl)acetic acid was prepared in a multistep process

starting from 2-bromo-4-chloro-6-fluoroaniline and 2,5-dimethoxytetrahydrofuran. Compds. of this invention showed IC50 values of 0.56 nM to 7.6 nM against rat squalene synthetase.

IT 937062-99-2P 937064-08-9P 937064-14-7P

937064-19-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tricyclic compds. such as pyrrolobenzoxazepine derivs. and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis)

RN 937062-99-2 CAPLUS

CN 5-Oxazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]-, methyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937064-08-9 CAPLUS

CN 5-Oxazolebutanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]-, methyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937064-14-7 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]-, methyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937064-19-2 CAPLUS

CN 5-Oxazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]-4-methyl-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.





L5 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2006:1224848 CAPLUS [Full-text](#)  
DN 146:134491

TI Chemical Database Mining through Entropy-Based Molecular Similarity  
Assessment of Randomly Generated Structural Fragment Populations

AU Batista, Jose; Bajorath, Juergen  
CS Department of Life Science Informatics, Rheinische  
Friedrich-Wilhelms-Universitaet, Bonn, D-53113, Germany

SO Journal of Chemical Information and Modeling (2007), 47(1), 59-68  
CODEN: JCISD8; ISSN: 1549-9596

PB American Chemical Society

DT Journal

LA English

AB The authors describe a novel approach to search for active compds. that is based on the generation of random mol. fragment populations. As a similarity-based methodol., fragment profiling does not depend on the use of predefined descriptors of mol. structure and properties and the design of chemical space representations. To adapt the generation and comparison of random fragment populations for large-scale compound screening, the authors compare different fragmentation schemes, introduce the concept of compound class-specific fragment frequencies, and develop a novel entropic similarity metric for compound ranking. The approach has been extensively tested on 15 different compound activity classes with varying degrees of intraclass structural diversity and produced promising results in these calcs., comparable to similarity searching using fingerprints. A key feature of fragment profile searching is that the calcn. of compound class-specific proportional Shannon entropy of random fragment distributions enables the identification of database mols. that share a significant number of signature substructures with known active compds.


IT 606928-75-0

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(chemical database mining through entropy-based mol. similarity assessment)

RN 606928-75-0 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-3-[2-(3,4-dihydro-1(2H)-pyridinyl)-2-oxoethyl]-5-(2,3-dimethoxyphenyl)-1,5-dihydro-, (3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2006:1147695 CAPLUS Full-text  
 DN 145:465761

TI Remedy for xanthoma containing squalene synthetase inhibitor  
 IN Shiomi, Masashi; Ito, Takashi; Tozawa, Ryuichi; Amano, Yuichiro  
 PA National University Corporation Kobe University, Japan; Takeda  
 Pharmaceutical Company Limited


SO PCT Int. Appl., 102pp.  
 CODEN: PIXXD2

DT Patent  
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006115193	A1	20061102	WO 2006-JP308402	20060421
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2006240710	A1	20061102	AU 2006-240710	20060421
	CA 2605365	A1	20061102	CA 2006-2605365	20060421
	EP 1889632	A1	20080220	EP 2006-745533	20060421
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	IN 2007KN03945	A	20080125	IN 2007-KN3945	20071015
	MX 2007012935	A	20080326	MX 2007-12935	20071017
	KR 2008015395	A	20080219	KR 2007-724160	20071019
	NO 2007005387	A	20080121	NO 2007-5387	20071022
	CN 101203243	A	20080618	CN 2006-80022653	20071224
PRAI	JP 2005-124781	A	20050422		
	WO 2006-JP308402	W	20060421		
	WO 2006-JP8402	W	20060421		
OS	MARPAT 145:465761				
AB	Disclosed is a preventive/remedy for xanthoma which contains a compound having an inhibitory effect on squalene synthase, its prodrug or its salt. For example, the effect of N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid (I) on xanthoma in rabbits was examined. Also, a capsule containing I 10 mg/capsule was formulated.				
IT	839723-32-9 839723-37-4 839723-87-4 839724-23-1 839724-36-6 839725-28-9 839725-30-3 913621-84-8				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (remedies for xanthoma containing squalene synthetase inhibitors)				
RN	839723-32-9 CAPLUS				
CN	5-Oxazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)				


Absolute stereochemistry.



RN 839723-37-4 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-87-4 CAPLUS

CN Benzeneacetic acid, 4-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-23-1 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-36-6 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-28-9 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-30-3 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid,  
3-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 913621-84-8 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2005:120907 CAPLUS Full-text  
 DN 142:219318  
 TI Preparation of benzoxazepine derivatives as squalene synthase inhibitors  
 IN Marui, Shogo; Miki, Takashi; Miura, Shoutarou; Nishimoto, Tomoyuki;  
 Nakada, Yoshihisa  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 239 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012272	A1	20050210	WO 2004-JP11293	20040730
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004260757	A1	20050210	AU 2004-260757	20040730
	CA 2534464	A1	20050210	CA 2004-2534464	20040730
	JP 2005068138	A	20050317	JP 2004-222658	20040730
	EP 1650201	A1	20060426	EP 2004-748264	20040730
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1832934	A	20060913	CN 2004-80022202	20040730
	BR 2004013009	A	20061003	BR 2004-13009	20040730
	RU 2337100	C2	20081027	RU 2006-106281	20040730
	MX 2006001007	A	20060427	MX 2006-1007	20060125
	KR 2006052906	A	20060519	KR 2006-701839	20060126
	IN 2006KN00235	A	20070803	IN 2006-KN235	20060131
	NO 2006001009	A	20060502	NO 2006-1009	20060301
	US 20080227770	A1	20080918	US 2008-566883	20080515
PRAI	JP 2003-285341	A	20030801		
	WO 2004-JP11293	W	20040730		
OS	MARPAT 142:219318				
GI					



AB The title compds. I (ring A and ring B each represents an optionally substituted benzene ring; ring C represents an optionally further substituted aromatic ring; R1 represents a lower alkyl optionally substituted by optionally substituted hydroxy; X1a represents a bond or optionally substituted lower alkylene; X1b represents a bond or optionally substituted lower alkylene; X2 represents a bond, O, or S; X3 represents a bond or an optionally substituted divalent hydrocarbon group; and Y represents optionally esterified or amidated carboxy) are prepared A process for preparing I is disclosed. Thus, (2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]methyl]-1,3-thiazol-5-yl]acetic acid was prepared in a multistep process from 2-(tert-butoxycarbonylamino)acetic acid and potassium monoethyl malonate. Compds. of this invention are said to show IC50 values of  $\leq 1 \mu\text{M}$  against squalene synthase. Formulations are given.

IT 839723-04-5P 839723-05-6P 839723-06-7P  
839723-07-6P 839723-08-9P 839723-09-0P  
839723-10-3P 839723-11-4P 839723-12-5P  
839723-13-6P 839723-14-7P 839723-15-8P  
839723-16-9P 839723-17-0P 839723-21-6P  
839723-22-7P 839723-23-8P 839723-24-9P  
839723-26-1P 839723-27-2P 839723-28-3P  
839723-30-7P 839723-31-8P 839723-32-9P  
839723-33-0P 839723-34-1P 839723-35-2P  
839723-36-3P 839723-37-4P 839723-38-5P  
839723-39-6P 839723-40-9P 839723-41-0P  
839723-43-2P 839723-44-3P 839723-45-4P  
839723-46-5P 839723-47-6P 839723-48-7P  
839723-49-8P 839723-50-1P 839723-51-2P  
839723-52-3P 839723-54-5P 839723-57-8P  
839723-58-9P 839723-59-0P 839723-60-3P  
839723-61-4P 839723-62-5P 839723-63-6P  
839723-65-8P 839723-66-9P 839723-67-0P  
839723-68-1P 839723-69-2P 839723-70-5P  
839723-71-6P 839723-72-7P 839723-73-8P  
839723-74-9P 839723-75-0P 839723-76-1P  
839723-77-2P 839723-78-3P 839723-79-4P  
839723-80-7P 839723-81-8P 839723-82-9P  
839723-83-0P 839723-86-3P 839723-87-4P  
839723-89-6P 839723-90-9P 839723-91-0P  
839723-93-2P 839723-94-3P 839723-95-4P  
839723-96-5P 839723-97-6P 839723-98-7P  
839723-99-8P 839724-00-4P 839724-01-5P  
839724-02-6P 839724-03-7P 839724-04-6P  
839724-05-9P 839724-06-0P 839724-07-1P  
839724-10-6P 839724-11-7P 839724-12-8P  
839724-13-9P 839724-14-0P 839724-15-1P  
839724-16-2P 839724-17-3P 839724-18-4P  
839724-19-5P 839724-20-8P 839724-22-0P  
839724-23-1P 839724-24-2P 839724-26-4P  
839724-29-7P 839724-30-0P 839724-32-2P  
839724-33-3P 839724-34-4P 839724-35-5P  
839724-36-6P 839724-37-7P 839724-38-8P  
839724-39-9P 839724-40-2P 839724-41-3P  
839724-42-4P 839724-43-5P 839724-44-6P  
839724-45-7P 839724-46-8P 839724-47-9P  
839724-48-0P 839724-49-1P 839724-50-4P  
839725-25-6P 839725-26-7P 839725-27-8P  
839725-28-9P 839725-29-0P 839725-30-3P  
839725-31-4P 839725-32-5P 839725-33-6P  
839725-34-7P 839725-35-6P 839725-36-9P

839725-37-0P 839725-38-1P 839725-39-2P  
839725-40-5P 839725-41-6P 839725-42-7P  
840494-06-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of benzoxazepine derivs. as squalene synthase inhibitors)

RN 839723-04-5 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-  
1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-  
3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-05-6 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-  
1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-  
3-yl]methyl]-4-methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-06-7 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-  
1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-  
3-yl]methyl]- $\alpha$ , $\alpha$ -dimethyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 839723-07-8 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-08-9 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-09-0 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-10-3 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-11-4 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[[1-(hydroxymethyl)cyclobutyl]methyl]-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-12-5 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[[1-(hydroxymethyl)cyclobutyl]methyl]-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-13-6 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-1-propyl-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-14-7 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-15-8 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-ethyl-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-16-9 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-

1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl)methyl]-4-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-17-0 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-21-6 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl)methyl]-β-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-22-7 CAPLUS

CN 2-Propenoic acid, 3-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-thiazolyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839723-23-8 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-24-9 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-26-1 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-27-2 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-β-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-28-3 CAPLUS

CN 2-Propenoic acid, 3-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-thiazolyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 839723-30-7 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, calcium salt (1:1) (CA INDEX NAME)

Absolute stereochemistry.






● Ca

RN 839723-31-8 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl-, calcium salt (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● Ca

RN 839723-32-9 CAPLUS

CN 5-Oxazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl-, calcium salt (1:1) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-33-0 CAPLUS

CN 5-Oxazolebutanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-34-1 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\alpha,\alpha$ -dimethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-35-2 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-36-3 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-37-4 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-38-5 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-1-propyl-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-39-6 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-ethyl-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-40-9 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-41-0 CAPLUS

CN 4-Oxazolepropanoic acid, 2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-43-2 CAPLUS

CN 1H-Pyrazole-1-butanoic acid, 4-carboxy-3-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-44-3 CAPLUS

CN 1H-Pyrazole-1-butanoic acid, 4-carboxy-5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-45-4 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 4-carboxy-3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-46-5 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 4-carboxy-5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-47-6 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1-(2-carboxyphenyl)-, 4-ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-48-7 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1-(3-carboxyphenyl)-, 4-ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-49-8 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1-(4-carboxyphenyl)-, 4-ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-50-1 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-(2-carboxyphenyl)-5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 839723-51-2 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-(3-carboxyphenyl)-5-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-52-3 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-(4-carboxyphenyl)-5-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-54-5 CAPLUS

CN 2-Propenoic acid, 3-[1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-1H-pyrazol-5-yl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839723-57-8 CAPLUS

CN 1,3,4-Oxadiazole-2-acetic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-58-9 CAPLUS

CN 1,3,4-Thiadiazole-2-acetic acid, 5-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-59-0 CAPLUS

CN 1,3,4-Thiadiazole-2-propanoic acid, 5-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-60-3 CAPLUS

CN 1,2,4-Oxadiazole-4(5H)-acetic acid,  
3-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-  
dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-  
oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-61-4 CAPLUS

CN 1,2,4-Oxadiazole-4(5H)-acetic acid,  
3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-  
hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-oxo-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 839723-62-5 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid,  
3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-  
hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA  
INDEX NAME)


Absolute stereochemistry.



RN 839723-63-6 CAPLUS

CN 1,2,4-Oxadiazole-5-acetic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-65-8 CAPLUS


CN 1H-1,2,4-Triazole-5-acetic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-66-9 CAPLUS  
 CN Benzoic acid, 3-[3-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]-5-hydroxy-1H-pyrazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-67-0 CAPLUS  
 CN Benzoic acid, 3-[3-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl)methyl]-5-hydroxy-1H-pyrazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 839723-68-1 CAPLUS  
 CN Benzoic acid, 4-[3-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]-5-hydroxy-1H-pyrazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-69-2 CAPLUS

CN Benzoic acid, 4-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-hydroxy-1H-pyrazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-70-5 CAPLUS

CN Benzoic acid, 4-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-ethoxy-1H-pyrazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-71-6 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 3-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-72-7 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 5-(carboxymethoxy)-3-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-73-8 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]phenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.






RN 839723-74-9 CAPLUS

CN Benzenepropanoic acid, 4-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-75-0 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]phenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 839723-76-1 CAPLUS

CN 2-Propenoic acid, 3-[3-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]phenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 839723-77-2 CAPLUS

CN 2-Propenoic acid, 3-[3-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]phenyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839723-78-3 CAPLUS

CN Benzenepropanoic acid, 3-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-79-4 CAPLUS

CN Benzenepropanoic acid, 3-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-80-7 CAPLUS

CN Benzenepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-81-8 CAPLUS

CN Benzenebutanoic acid, 4-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-

3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-82-9 CAPLUS

CN Benzenepropanoic acid, 4-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]-1-hydroxyethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-83-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-86-3 CAPLUS

CN Acetic acid, 2-[4-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-87-4 CAPLUS

CN Benzeneacetic acid, 4-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-89-6 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-90-9 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl)methyl]-4-(2-phenylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-91-0 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl)methyl]-4-(2-phenylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-93-2 CAPLUS

CN 1H-Pyrazole-5-propanoic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-94-3 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-95-4 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-96-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-β-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-97-6 CAPLUS

CN 1H-Pyrazole-5-propanoic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-β-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.






RN 839723-98-7 CAPLUS

CN 2-Propenoic acid, 3-[1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-1H-pyrazol-4-yl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839723-99-8 CAPLUS

CN 1,3,4-Thiadiazole-2-butanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-00-4 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\alpha$ -(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-01-5 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-02-6 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, calcium salt (2:1) (CA INDEX NAME)

Absolute stereochemistry.




● 1/2 Ca

RN 839724-03-7 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-α-(phenylmethylene)-, (αZ)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839724-04-8 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-α-hydroxy-, (αR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-05-9 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\beta$ , $\beta$ -dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-06-0 CAPLUS

CN 5-Thiazoleacetic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-07-1 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-10-6 CAPLUS

CN 4-Thiazoleacetic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-11-7 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3R,5S)-1-(3-(acetyloxy)-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-12-8 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-β-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-13-9 CAPLUS

CN 2-Propenoic acid, 3-[2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-4-thiazolyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839724-14-0 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-15-1 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- $\beta,\beta$ -dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-16-2 CAPLUS

CN 4-Thiazoleacetic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-17-3 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-18-4 CAPLUS

CN 4-Thiazoleacetic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]-1-hydroxyethyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 839724-19-5 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]-1-hydroxyethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-20-8 CAPLUS

CN 2-Thiopheneacetic acid, 5-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-22-0 CAPLUS

CN 5-Thiazoleacetic acid, 2-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-23-1 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-24-2 CAPLUS

CN 4-Thiazoleacetic acid, 2-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-26-4 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[{(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]-4-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-29-7 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[{(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-30-0 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[{(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-32-2 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-33-3 CAPLUS

CN 5-Oxazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-34-4 CAPLUS

CN 4-Oxazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-

(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-35-5 CAPLUS

CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-36-6 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-37-7 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid,  
3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-  
1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-38-8 CAPLUS

CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-  
dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-  
benzoxazepin-3-yl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-39-9 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid,


3-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-40-2 CAPLUS  
 CN 1,2,4-Oxadiazole-5-propanoic acid,  
 3-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-  
 1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-41-3 CAPLUS  
 CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-  
 4,1-benzoxazepin-3-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-42-4 CAPLUS  
 CN 1,2,4-Oxadiazole-5-propanoic acid,  
 3-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-  
 1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 839724-43-5 CAPLUS  
 CN 1,2,4-Oxadiazole-5-butyric acid, 3-[[ (3R,5S)-7-chloro-5-(2,3-  
 dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-  
 benzoxazepin-3-yl]methyl]-β-methyl-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-44-6 CAPLUS



CN Acetic acid, 2-[[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]methyl]thio]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-45-7 CAPLUS

CN Propanoic acid, 2-[[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]methyl]thio]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-46-8 CAPLUS

CN Acetic acid, 2-[[[1-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]-1-methylethyl]thio]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-47-9 CAPLUS

CN Acetic acid, 2-[[1-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-1-methylethyl]thio]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-48-0 CAPLUS

CN Acetic acid, 2-[[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-1-methylethyl]thio]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-49-1 CAPLUS

CN Propanoic acid, 2-[[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]methyl]thio]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-50-4 CAPLUS

CN Acetic acid, 2-[[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-thiadiazol-5-yl]thio]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-25-6 CAPLUS

CN Propanoic acid, 2-[[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-thiadiazol-5-yl]thio]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-26-7 CAPLUS

CN Butanoic acid, 4-[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-thiadiazol-5-yl]thio]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-27-8 CAPLUS

CN Acetic acid, 2-[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-thiadiazol-5-yl]thio]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-28-9 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid,  
3-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-29-0 CAPLUS

CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-30-3 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid,  
3-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-31-4 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid,  
3-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-32-5 CAPLUS


CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 839725-33-6 CAPLUS  
 CN 1,2,4-Oxadiazole-5-propanoic acid,  
 3-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 839725-34-7 CAPLUS  
 CN 5-Thiazolebutanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 839725-35-8 CAPLUS  
 CN 5-Thiazolebutanoic acid, 2-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-36-9 CAPLUS

CN 1,3,4-Oxadiazole-2-butanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-37-0 CAPLUS

CN 1,3,4-Oxadiazole-2-propanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 839725-38-1 CAPLUS

CN 5-Thiazolepropanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\beta$ -hydroxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 839725-39-2 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-thiazolyl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839725-40-5 CAPLUS

CN 5-Thiazolepropanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-41-6 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazin-3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-42-7 CAPLUS


CN 2-Thiophenebutanoic acid, 5-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840494-06-6 CAPLUS  
 CN Benzenepropanoic acid, 4-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 839724-52-6P 839724-57-1P 839724-60-6P  
 839724-62-8P 839724-63-9P 839724-64-0P  
 839724-66-2P 839724-67-3P 839724-70-8P  
 839724-71-9P 839724-72-0P 839724-73-1P  
 839724-74-2P 839724-75-3P 839724-76-4P  
 839724-78-6P 839724-79-7P 839724-81-1P  
 839724-82-2P 839724-84-4P 839724-85-5P  
 839724-86-6P 839724-87-7P 839724-88-8P  
 839724-90-2P 839724-91-3P 839724-92-4P  
 839724-94-6P 839724-95-7P 839724-96-8P  
 839724-97-9P 839724-98-0P 839724-99-1P  
 839725-00-7P 839725-04-1P 839725-06-3P  
 839725-07-4P 839725-14-3P 839725-17-6P  
 839725-43-8P 839725-44-9P 839725-47-2P  
 839725-48-3P 839725-49-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of benzoxazepine derivs. as squalene synthase inhibitors)

RN 839724-52-6 CAPLUS  
 CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-57-1 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-60-6 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-62-8 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-β-oxo-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-63-9 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-β-hydroxy-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-64-0 CAPLUS

CN 2-Propenoic acid, 3-[2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-thiazolyl]-, ethyl ester, (2E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839724-66-2 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-methyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-67-3 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-70-8 CAPLUS

CN 5-Thiazolecarboxylic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-2-methyl-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-71-9 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-72-0 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-73-1 CAPLUS

CN 5-Oxazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-74-2 CAPLUS

CN 4-Oxazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-methyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-75-3 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.






RN 839724-76-4 CAPLUS

CN 1H-Pyrazole-1-butanoic acid, 3-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-(ethoxycarbonyl)-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-78-6 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-79-7 CAPLUS

CN 1H-Pyrazole-3-acetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-81-1 CAPLUS

CN 1,3,4-Oxadiazole-2-acetic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-82-2 CAPLUS

CN 1,3,4-Thiadiazole-2-acetic acid, 5-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-84-4 CAPLUS

CN 1,3,4-Thiadiazole-2-propanoic acid, 5-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-85-5 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-3-[(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)methyl]-5-(2,3-dimethoxyphenyl)-1,5-dihydro-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-86-6 CAPLUS

CN 1,2,4-Oxadiazole-4(5H)-acetic acid,  
3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-87-7 CAPLUS


CN Benzoic acid, 4-[3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-ethoxy-1H-pyrazol-1-yl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-88-8 CAPLUS  
 CN Benzoic acid, 4-[3-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-hydroxy-1H-pyrazol-1-yl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-90-2 CAPLUS  
 CN 2-Propenoic acid, 3-[4-[2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]phenyl]-, ethyl ester, (2E)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



RN 839724-91-3 CAPLUS  
 CN Benzenepropanoic acid, 4-[2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-92-4 CAPLUS

CN Benzenepropanoic acid, 4-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-94-6 CAPLUS

CN Benzenepropanoic acid, 4-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-95-7 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-96-8 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2,2-dimethylpropyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-97-9 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2,2-dimethylpropyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-α-(phenylmethyl)-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-98-0 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\alpha$ -(phenylmethyl)-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-99-1 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[3-[[[(1,1-dimethylethyl)dimethylsilyloxy]-2,2-dimethylpropyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\alpha$ -(hydroxyphenylmethyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.






RN 839725-00-7 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2,2-dimethylpropyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\alpha$ -(phenylmethylene)-, ethyl ester, ( $\alpha$ Z)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839725-04-1 CAPLUS

CN 4-Thiazolepropanenitrile, 2-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- $\alpha$ -[[[(1,1-dimethylethyl)dimethylsilyl]oxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-06-3 CAPLUS

CN 4-Thiazoleacetic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]-1-hydroxyethyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-07-4 CAPLUS

CN 4-Thiazoleacetic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-14-3 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 839725-17-6 CAPLUS

CN Acetic acid, 2-[[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-

1,2,4-thiadiazol-5-yl]thiol-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-43-8 CAPLUS

CN Propanoic acid, 2-[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-thiadiazol-5-yl]thiol]-2-methyl-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-44-9 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-thiadiazol-5-yl]thiol]-2-oxo-4,1-benzoxazepin-3-yl]methyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-47-2 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]-1-[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]-1,2,4-thiadiazol-5-yl]thiol-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-48-3 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid,  
3-[2-[(3R, 5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-49-4 CAPLUS

CN 1,3,4-Oxadiazole-2-propanoic acid,  
5-[[ (3R, 5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2003:767796 CAPLUS Full-text

DN 139:276921

TI Preparation of benzoxazepine derivatives as squalene synthetic enzyme inhibitors

IN Miki, Takashi; Kori, Masaki

PA Takeda Chemical Industries, Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 36 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003277377	A	20031002	JP 2003-10125	20030117
	CA 2513170	A1	20040805	CA 2004-2513170	20040115
	WO 2004064865	A1	20040805	WO 2004-JP234	20040115
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
	EP 1600166	A1	20051130	EP 2004-702450	20040115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2004107361	A	20040408	JP 2004-9836	20040116
	JP 2004315500	A	20041111	JP 2004-9617	20040116
	US 20060052362	A1	20060309	US 2005-542322	20050713
	US 20080113965	A1	20080515	US 2008-6506	20080103
PRAI	JP 2002-10623	A	20020118		
	JP 2003-10125	A	20030117		
	JP 2003-93591	A	20030331		
	WO 2004-JP234	W	20040115		
	US 2005-542322	A1	20050713		
OS	MARPAT 139:276921				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. I [wherein W = halo; R1 = alkyl; R2 = CHO or (un)substituted alkyl; m = 1-3; n = 0-2; R4 = H or -(CH2)p-R5; R5 = (un)substituted CO2H; p = 0-3; etc.] and salts and prodrugs thereof are prepared as squalene synthetic enzyme inhibitors. I are useful as a lipid decrease medicine and a high fat blood disease medicine (no data). Thus, the compound II was prepared in a multi-step synthesis. II showed IC50 of 45 nM against human squalene synthetic enzyme. Formulations containing I as an active ingredient were also described.

IT 606928-79-4P


RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(drug candidate; preparation of benzoxazepine derivs. as squalene synthetic enzyme inhibitors)

RN 606928-79-4 CAPLUS

CN 4-Pyridineacetic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro- (CA INDEX NAME)

Absolute stereochemistry.




IT 606928-80-7P 606928-81-8P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; preparation of benzoxazepine derivs. as squalene synthetic enzyme inhibitors)

RN 606928-80-7 CAPLUS

CN 4-Pyridineacetic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro-, (4S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 606928-81-8 CAPLUS

CN 4-Pyridineacetic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro-, (4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 606928-72-8P 606928-75-0P 606928-77-2P


606928-78-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate; preparation of benzoxazepine derivs. as squalene synthetic enzyme inhibitors)

RN 606928-73-8 CAPLUS

CN 4-Pyridineacetic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,6-tetrahydro-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 606928-75-0 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-3-[2-(3,4-dihydro-1(2H)-pyridinyl)-2-oxoethyl]-5-(2,3-dimethoxyphenyl)-1,5-dihydro-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 606928-77-2 CAPLUS

CN 4-Pyridineacetic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethyl-3-oxopropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 606928-78-3 CAPLUS

CN 4-Pyridineacetic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.





IT 606928-74-9P 606929-11-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzoxazepine derivs. as squalene synthetic enzyme inhibitors)

RN 606928-74-9 CAPLUS

CN 4-Pyridineacetic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,6-tetrahydro- (CA INDEX NAME)


Absolute stereochemistry.



RN 606929-11-7 CAPLUS

CN 4-Pyridineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2003:22711 CAPLUS Full-text  
 DN 138:83384

TI Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase

IN Sugiyama, Yasuo; Nishimoto, Tomoyuki; Kiyota, Yoshihiro

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 121 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003002147	A1	20030109	WO 2002-JP6495	20020627
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2451163	A1	20030109	CA 2002-2451163	20020627
	AU 2002313277	A1	20030303	AU 2002-313277	20020627
	JP 2003081873	A	20030319	JP 2002-188133	20020627
	EP 1407782	A1	20040414	EP 2002-738822	20020627
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 20040204500	A1	20041014	US 2003-480707	20031211
	US 20060241096	A1	20061026	US 2006-473560	20060623
	US 20080132483	A1	20080605	US 2008-9277	20080117
PRAI	JP 2001-197419	A	20010628		
	WO 2002-JP6495	W	20020627		
	US 2003-480707	A3	20031211		
	US 2006-473560	B1	20060623		

OS MARPAT 138:83384

AB Preventives/remedies for organ functional disorders, preventives/remedies for organ dysfunction and preventives/remedies for obesity and sequels thereof which contain a compound having an effect of increasing ubiquinone, its salt or prodrugs of the same; and ubiquinone increasing agents containing a compound having a squalene synthase inhibitory effect, its salt or prodrugs of the same.

IT 189060-33-1 189060-48-8


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase)

RN 189060-33-1 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(2H-tetrazol-5-ylmethyl)-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-48-8 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(2H-tetrazol-5-ylmethyl)-, (3R,5S)-(CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2002:368342 CAPLUS Full-text

DN 136:359669

TI High-density lipoprotein-cholesterol level elevating agent

IN Nishimoto, Tomoyuki; Tozawa, Ryuichi; Kori, Masakuni; Amano, Yuichiro

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 111 pp.

CODEN: PIXXD2


DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002038180	A1	20020516	WO 2001-JP9802	20011109
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2428669	A1	20020516	CA 2001-2428669	20011109
	AU 2002012741	A	20020521	AU 2002-12741	20011109
	JP 2002205956	A	20020723	JP 2001-344074	20011109
	JP 4138299	B2	20080827		
	EP 1332763	A1	20030806	EP 2001-981043	20011109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 20040063750	A1	20040401	US 2003-416239	20030506
	US 20080058310	A1	20080306	US 2007-810887	20070607
PRAI	JP 2000-342607	A	20001109		
	WO 2001-JP9802	W	20011109		
	US 2003-416239	A1	20030506		
OS	MARPAT 136:359669				
AB	Disclosed is a novel high-d. lipoprotein (HDL)-cholesterol level elevating agent containing a compound which has a squalene synthase inhibitory effect. The HDL-cholesterol-elevating effect of N-[[[3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl]acetyl]piperidine-4-acetic acid (I) in common marmoset was examined Also, a tablet containing I 50, D-mannitol 50, corn starch 33.9, croscarmellose sodium 40, hydroxypropyl cellulose 5.5, and magnesium stearate 0.6 mg was prepared				
IT	189060-33-1 189060-48-8				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (high-d. lipoprotein-cholesterol level elevating agents containing squalene synthase inhibitors)				
RN	189060-33-1 CAPLUS				
CN	4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(2H-tetrazol-5-ylmethyl)-, (3R,5S)- (CA INDEX NAME)				


Absolute stereochemistry.



RN 189060-48-8 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(2H-tetrazol-5-ylmethyl)-, (3R,5S)-(CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1997:317788 CAPLUS Full-text

DN 126:293368

OREF 126:56816h,56817a

TI Benzoxazepine compounds, their production and use as lipid lowering agents

IN Yukimasa, Hidefumi; Sugiyama, Yasuo; Tozawa, Ryuichi

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 112 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9710224	A1	19970320	WO 1996-JP2596	19960912
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2231052	A1	19970320	CA 1996-2231052	19960912
	CA 2231052	C	20071113		
	AU 9669442	A	19970401	AU 1996-69442	19960912
	JP 09136880	A	19970527	JP 1996-242378	19960912
	JP 3479796	B2	20031215		
	EP 862562	A1	19980909	EP 1996-930365	19960912
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1196052	A	19981014	CN 1996-196892	19960912
	CN 1072649	C	20011010		
	EP 1097928	A1	20010509	EP 2000-126672	19960912
	EP 1097928	B1	20080716		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AT 202774	T	20010715	AT 1996-930365	19960912
	ES 2158344	T3	20010901	ES 1996-930365	19960912
	PT 862562	T	20011130	PT 1996-930365	19960912
	AT 401315	T	20080815	AT 2000-126672	19960912
	ZA 9702134	A	19990604	ZA 1997-2134	19970312
	US 6110909	A	20000829	US 1998-43265	19980312
	US 6613761	B1	20030902	US 2000-587947	20000606
	JP 2001097963	A	20010410	JP 2000-323310	20001018
	JP 4021612	B2	20071212		
	GR 3036707	T3	20011231	GR 2001-401564	20010926
	US 20040072819	A1	20040415	US 2003-606152	20030624
	US 20070117787	A1	20070524	US 2006-638066	20061212
	JP 2007332154	A	20071227	JP 2007-210503	20070810
	US 20080153801	A1	20080626	US 2007-986280	20071119
FRAI	JP 1995-235457	A	19950913		
	EP 1996-930365	A3	19960912		
	JP 1996-242378	A3	19960912		
	WO 1996-JP2596	W	19960912		
	ZA 1997-2134	A	19970312		
	US 1998-43265	A3	19980312		
	US 2000-587947	A1	20000606		
	JP 2000-323310	A3	20001018		
	US 2003-606152	B1	20030624		
	US 2006-638066	B1	20061212		
OS	MARPAT 126:293368				

GI




- AB New benzoxazepines I [R = alkyl, hydroxyalkyl; R1 = alkyl; R2 = halogen; R3 = (un)substituted CONH2, heterocyclic group having a deprotonatable hydrogen atom] were prepared for use as cholesterol and triglyceride lowering agent. Thus, I [R = CH2CMe3, R1 = Me, R2 = Cl, R3 = CO2H] was amidated, dehydrated to the nitrile, and cyclized with Me3SiN3 to give I [R = CH2CMe3, R1 = Me, R2 = Cl, R3 = 5-tetrazolyl] which had a squalene synthetase inhibiting IC50 of 11X10<sup>-9</sup> M.
- IT 189060-33-1P 189060-48-8P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of arylbenzoxazepinones as hypolipemic agents)
- RN 189060-33-1 CAPLUS
- CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(2H-tetrazol-5-ylmethyl)-, (3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.




- RN 189060-48-8 CAPLUS
- CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(2H-tetrazol-5-ylmethyl)-, (3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.



```
=> d l2; d his; log y
L2 HAS NO ANSWERS
L1          STR
```



Structure attributes must be viewed using STN Express query preparation.  
 L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 20:09:13 ON 28 FEB 2009)

FILE 'REGISTRY' ENTERED AT 20:09:44 ON 28 FEB 2009

```
L1          STRUCTURE UPLOADED
L2          QUE L1
L3          14 S L2
L4          211 S L2 FUL
```

FILE 'CAPLUS' ENTERED AT 20:10:22 ON 28 FEB 2009

```
L5          10 S L4
```

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	57.40	243.50
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-8.20	-8.20

STN INTERNATIONAL LOGOFF AT 20:11:47 ON 28 FEB 2009